Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally. Researchers are exploring the use of a new drug called ataciguat to manage AVS. Results from preclinical and clinical studies show that ataciguat has the potential to significantly slow disease progression.
Read more …New drug may reduce need for aortic valve surgeries by slowing disease progression
Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), have shown significant effectiveness in both lowering blood sugar levels and aiding weight loss due to their unique pharmacological mechanisms. A research team assessed the impact of GLP-1 receptor agonist in weight loss through genetic studies, aiming to understand whether the use of these medications reduces weight due to muscle or fat mass loss. This genetic study revealed that GLP-1 receptor agonists reduce weight by reducing more fat mass than muscle mass.
Read more …Genetic evidence that diabetes drug GLP-1 receptor agonists achieve weight loss primarily by...